PYXS — Pyxis Oncology Balance Sheet
0.000.00%
- $204.93m
- $47.90m
- 40
- 21
- 64
- 37
Annual balance sheet for Pyxis Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 19.7 | 8.08 | 275 | 179 | 119 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | — | 0.598 | 0.021 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 19.7 | 8.1 | 279 | 187 | 125 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.076 | 1.94 | 1.24 | 24.8 | 24.8 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 19.8 | 10.2 | 280 | 211 | 174 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.733 | 3.69 | 18.7 | 31.6 | 25.8 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.739 | 3.85 | 18.7 | 50.6 | 48 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 19.1 | 6.3 | 261 | 161 | 126 |
Total Liabilities & Shareholders' Equity | 19.8 | 10.2 | 280 | 211 | 174 |
Total Common Shares Outstanding |